EXTON, Pa.--(BUSINESS WIRE)--Absorption Systems, LP, today announced that the company has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the U.S. Food and Drug Administration (FDA) to develop an innovative tool to help determine the potential for drug-drug interactions. Absorption Systems will use the $215,000 Phase I grant to further develop the company’s CellPort Technologies™ assay system, a suite of preclinical in vitro test systems designed to provide definitive data regarding interactions between new drugs under investigation and specific transporter proteins that have been identified by the FDA as key indicators of drug safety. The current suite of CellPort Technologies test systems includes assays for three different human drug efflux transporters.
